Advanced glycation end-products and advanced oxidation protein products in patients with insulin dependent diabetes mellitus and first degree relatives

Medical Journal of Bakirkoy

Volumn 7, Issue 4, 2011, Pages 130-135

  Kural, Alev ^a   Toker, Aysun ^b   Seval, Hatice ^a   Döventaş, Yasemin ^a   Basinoǧlu, Filiz ^a   Koldaş, Macit ^a   Saǧlam, Zuhal A ^c  

^a Haseki Training and Research Hospital Biochemistry Laboratory   (Turkey)

^b Yoncali Physical Therapy and Rehabilitation Hospital   (Turkey)

^c HASEKI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Advanced glycation end products; Advanced oxidation protein products; Diabetes complications; First degree relatives; Type i diabetes mellitus

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED OXIDATION PROTEIN PRODUCT;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; FEMALE; FIRST DEGREE RELATIVE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; OXIDATIVE STRESS; RELATIVE;

EID: 83755194714     PISSN: 13059327     EISSN: None     Source Type: Journal    
DOI: 10.5350/BTDMJB201107402     Document Type: Article

References (24)

1. Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocrine Rev 1994; 15: 516-542.
2. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-412.
3. Piwowar A, Knapik-Kordecka M, Szczecinska J, Warwas M. Plasma glycooxidation protein products in type 2 diabetic patients with nephropaty. Diabetes Metab Res Rev 2008; 24: 549-553.
4. Abou-Seif MA, Youssef AA. Evaluation of some biochemical changes in diabetic patients. Clin Chim Acta 2004; 346: 161-170.
5. Martin-Gallan P, Carrascosa A, Gussinye M, Dominguez C. Biomarkers of diabetes associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med 2003; 34: 1563-1574.
6. Baskol G, Gumus K, Öner A, Arda H, Karaküçük S. The role of advanced oxidation protein products and total thiols in diabetic retinopathy. Eur J Ophthalmol 2008; 18: 792-798.
7. Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 2001; 56: 1-21.
8. Gil-del Valle L, de la C Millian L, Toledo A, Vilaro N, Tapanes R, Otero MA. Altered redox status in patients with diabetes mellitus type I. Pharmacol Res 2005; 51: 375-380.
9. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-1313.
10. Witko-Sarsat V, Friedlander M, Nguyen-Khoa T, et al. Advanced oxidation protein products as novel mediators of inflamation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-2532.
11. Alderman CJ, Shah S, Foreman JC, Chain BM, Katz DR. The role of advanced oxidation protein products in regulation of dendritic cell function. Free Radic Biol Med 2002; 32: 377-385.
12. Descamps-Latscha B, Witko-Sarsat V. Importance of oxidatively modified proteins in chronic renal failure. Kidney Int Suppl 2001; 78: 108-113.
13. Tsukahara H, Sekine K, Uchiyama M, et al. Formation of advanced glycosylation end products and oxidative stress in young patients with type 1 diabetes. Pediatr Res 2003; 54: 419-424.
14. Selmeci L, Szekely M, Soos P, et al. Human blood pasma advanced oxidation protein products (AOPP) correlates with fibrinogen levels. Free Radic Res 2006; 40: 952-958.
15. Friedewald WT, Levry RI, Frederickson DS. Estimation of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
16. Kalousova M, Skrha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 2002; 51: 597-604.
17. Vlassara H. Recent progress in advanced glycation end products and diabetic complications. Diabetes 1997; 46: 19-25.
18. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9.
19. Hattori Y, Suzuki M, Hattori S, Kasai K. Vascular smooth muscle cell activation by glycated albumin (Amadori adducts). Hypertension 2002; 39: 22-28.
20. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
21. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stres by the interaction of advanced glycation end products with their receptor/binding proteins. J Biol Chem 1994; 269: 9889-9897.
22. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products trigger a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stres. J Biol Chem 1997; 272: 17810-17814.
23. Retinopathy and nephropathy in patients with type I diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial, Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000; 342: 381-389.
24. Piwowar A, Knapik-Kordecka M, Warwas M. AOPP and its relation with selected markers of oxidative /antioxidative system in type 2 diabetes mellitus. Diabetes Res Clin Pract 2007; 77: 188-192.